247 related articles for article (PubMed ID: 11014444)
1. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy.
Parsa AT; Chakrabarti I; Hurley PT; Chi JH; Hall JS; Kaiser MG; Bruce JN
Neurosurgery; 2000 Oct; 47(4):993-9; discussion 999-1000. PubMed ID: 11014444
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model.
Kaiser MG; Parsa AT; Fine RL; Hall JS; Chakrabarti I; Bruce JN
Neurosurgery; 2000 Dec; 47(6):1391-8; discussion 1398-9. PubMed ID: 11126910
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation.
Biasibetti E; Valazza A; Capucchio MT; Annovazzi L; Battaglia L; Chirio D; Gallarate M; Mellai M; Muntoni E; Peira E; Riganti C; Schiffer D; Panciani P; Lanotte M
Comp Med; 2017 Mar; 67(2):147-156. PubMed ID: 28381315
[TBL] [Abstract][Full Text] [Related]
5. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors.
Saleh M; Wiegmans A; Malone Q; Stylli SS; Kaye AH
J Natl Cancer Inst; 1999 Mar; 91(5):438-45. PubMed ID: 10070943
[TBL] [Abstract][Full Text] [Related]
6. Modulation of tumor immunogenicity of rat glioma cells by s-Myc expression: eradication of rat gliomas in vivo.
Asai A; Miyagi Y; Hashimoto H; Lee SH; Mishima K; Sugiyama A; Tanaka H; Mochizuki T; Yasuda T; Kuchino Y
Cell Growth Differ; 1994 Nov; 5(11):1153-8. PubMed ID: 7848917
[TBL] [Abstract][Full Text] [Related]
7. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic activity of endostatin inhibits C6 glioma growth.
Peroulis I; Jonas N; Saleh M
Int J Cancer; 2002 Feb; 97(6):839-45. PubMed ID: 11857365
[TBL] [Abstract][Full Text] [Related]
9. Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
Carson WE; Jakowatz JG; Yamamoto R; Fitzgerald T; Gupta S; Vayuvegula B; Lucci JA; Beckman MT; Dulkanchainun S; Granger GA
J Immunother (1991); 1991 Apr; 10(2):131-40. PubMed ID: 2043593
[TBL] [Abstract][Full Text] [Related]
10. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12-based immunotherapy against rat 9L glioma.
Jean WC; Spellman SR; Wallenfriedman MA; Hall WA; Low WC
Neurosurgery; 1998 Apr; 42(4):850-6; discussion 856-7. PubMed ID: 9574650
[TBL] [Abstract][Full Text] [Related]
12. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
Zhu X; Lu C; Xiao B; Qiao J; Sun Y
J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene.
Liau LM; Fakhrai H; Black KL
Neurol Res; 1998 Dec; 20(8):742-7. PubMed ID: 9864741
[TBL] [Abstract][Full Text] [Related]
14. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
Clavreul A; Delhaye M; Jadaud E; Menei P
J Neurooncol; 2006 Aug; 79(1):9-17. PubMed ID: 16575532
[TBL] [Abstract][Full Text] [Related]
15. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas.
Barth RF
J Neurooncol; 1998 Jan; 36(1):91-102. PubMed ID: 9525831
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model.
Engelhard HH; Duncan HA; Kim S; Criswell PS; Van Eldik L
Neurosurgery; 2001 Mar; 48(3):616-24; discussion 624-5. PubMed ID: 11270553
[TBL] [Abstract][Full Text] [Related]
17. Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors.
Iwadate Y; Tagawa M; Namba H; Oga M; Kawamura K; Tasaki K; Sakiyama S; Yamaura A
Cancer Gene Ther; 2000 Sep; 7(9):1263-9. PubMed ID: 11023199
[TBL] [Abstract][Full Text] [Related]
18. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
Okada H; Villa L; Attanucci J; Erff M; Fellows WK; Lotze MT; Pollack IF; Chambers WH
Gene Ther; 2001 Aug; 8(15):1157-66. PubMed ID: 11509946
[TBL] [Abstract][Full Text] [Related]
19. Morphometrical characterization of two glioma models in the brain of immunocompetent and immunodeficient rats.
Saini M; Bellinzona M; Meyer F; Cali G; Samii M
J Neurooncol; 1999 Mar; 42(1):59-67. PubMed ID: 10360479
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and limitations of the rat model by C6 gliomas implanted at the subcutaneous region.
Watanabe K; Sakamoto M; Somiya M; Amin MR; Kamitani H; Watanabe T
Neurol Res; 2002 Jul; 24(5):485-90. PubMed ID: 12117320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
